Japan handles reimbursement for AI-driven medical devices by evaluating their clinical effectiveness, safety, and cost-effectiveness under MHLW and Chuikyo. Devices must demonstrate clear healthcare benefits, such as improved diagnostics or efficiency. Regulatory approval by PMDA is required, and innovative AI devices may receive premium reimbursement under the NHI system if they provide significant advancements.
